Skip to main content

Putting IL17i into ‘focus’ for SpA-associated uveitis The longest studied drug for uveitis in SpA has been monocol

Social Author Name
Dr. John Cush
Tweet Content
Putting IL17i into ‘focus’ for SpA-associated uveitis The longest studied drug for uveitis in SpA has been monocolonal TNFi Abs. Reductions of acute anterior uveitis have been found with etanercept but less impressively than adalimumab, infliximab, and in my opinion less than https://t.co/AUEct0FxmU

Psoriatic Arthritis: Hit hard and Early Two studies found no significant benefit of early biologics over standard meth

Social Author Name
Dr. John Cush
Tweet Content
Psoriatic Arthritis: Hit hard and Early Two studies found no significant benefit of early biologics over standard methotrexate treatment, but they did not focus on poor prognosis cases. The SPEED trial, funded by the NIHR, aimed to compare disease activity in 192 PsA patients https://t.co/pS9DdOOVCV

The Value of Kidney Biopsy in Autoimmune Diseases Dr. Andrea Fava shares his perspective from the EULAR 2025 meeting i

Social Author Name
Dr. John Cush
Tweet Content
The Value of Kidney Biopsy in Autoimmune Diseases Dr. Andrea Fava shares his perspective from the EULAR 2025 meeting in Barcelona, Spain. https://t.co/CA6Ak2scKb https://t.co/EK5wdpbzrl

EULAR Daily Recap: Day 3 Catch up on the biggest breakthroughs, standout sessions, and expert insights from day three

Social Author Name
Dr. John Cush
Tweet Content
EULAR Daily Recap: Day 3 Catch up on the biggest breakthroughs, standout sessions, and expert insights from day three of EULAR 2025. Listen to panelists break down the key highlights and what they mean for the future of rheumatology. Panelists: Drs. Yuz Yusof, Aurelie Najm, https://t.co/jmXUDV8odR

ALTO: Long-term Outcomes of APIPPRA Dr. Mrinalini Dey interviews Professor Andrew Cope about abstract OP0004, on the l

Social Author Name
Dr. John Cush
Tweet Content
ALTO: Long-term Outcomes of APIPPRA Dr. Mrinalini Dey interviews Professor Andrew Cope about abstract OP0004, on the long term outcome of APIPPRA patients - the ALTO study, at the EULAR 2025 meeting in Barcelona, Spain. https://t.co/9wVZSXbi6r https://t.co/fm77qDoTwm
Trends and Innovations from Barcelona (6.20.2025)

Dr. Jack Cush reviews highlights, trends and novel studies from EULAR 2025 in Barcelona from last week.

EULAR 2025 – Day 4 Report Saturday was the final day of EULAR, and included several lectures, but mostly late breaki

Social Author Name
Dr. John Cush
Tweet Content
EULAR 2025 – Day 4 Report Saturday was the final day of EULAR, and included several lectures, but mostly late breaking abstracts and new EULAR guidelines - notably on Rheumatoid Arthritis and another on Interstitial Lung disease in connective tissue disorders. https://t.co/ZJ1pHQJTbK

Toward Long-Term Prevention of Rheumatoid Arthritis: Are We Closer? As earlier diagnosis and treatment of rheumatoid a

Social Author Name
Dr. John Cush
Tweet Content
Toward Long-Term Prevention of Rheumatoid Arthritis: Are We Closer? As earlier diagnosis and treatment of rheumatoid arthritis (RA) have resulted in greatly improved clinical outcomes, the focus of current research has now shifted to preventing the development of RA altogether. https://t.co/HGbXVLVuSC

Difficult to Treat Axial Spondyloarthritis Drs. Antoni Chan and Martina Magrey discuss abstract POS0117 presented at t

Social Author Name
Dr. John Cush
Tweet Content
Difficult to Treat Axial Spondyloarthritis Drs. Antoni Chan and Martina Magrey discuss abstract POS0117 presented at the 2025 EULAR meeting in Barcelona. https://t.co/isv05fzV1d https://t.co/Ji24s9qSZF
Subscribe to
×